| Date | Panel | Item | Activity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacogenomics_Paediatric v0.50 | HLA-B |
David Metz changed review comment from: HLA-B*15:02: Increased carbamazepine-induced SJS/TEN (CPIC guideline, 29392710). Increase oxcarbazepine-induced SJS/TEN (CPIC guideline, 29392710). Increased lamotrogine-induced SJS/TEN (meta-analysis, 25428396). Increased phenytoin-induced SJS/TEN (moderate association, 23692434). PMID 26094938 HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701 and Abacavir hypersensitivity. 25934581, 22378157 HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 PMID 32714190 (review article) HLA-B*57:01, carbamazepine and SJS/TEN. HLA-B*15:11, carbamazepine and SJS/TEN. HLA-B*13:01, dapsone and DRESS (29458119); to: HLA-B*15:02: Increased carbamazepine-induced SJS/TEN (CPIC guideline, 29392710). Increase oxcarbazepine-induced SJS/TEN (CPIC guideline, 29392710). Increased lamotrogine-induced SJS/TEN (meta-analysis, 25428396). Increased phenytoin-induced SJS/TEN (25099164). PMID 26094938 HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701 and Abacavir hypersensitivity. 25934581, 22378157 HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 PMID 32714190 (review article) HLA-B*57:01, carbamazepine and SJS/TEN. HLA-B*15:11, carbamazepine and SJS/TEN. HLA-B*13:01, dapsone and DRESS (29458119) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.50 | HLA-B |
David Metz changed review comment from: HLA-B*15:02: Increased carbamazepine-induced SJS/TEN (CPIC guideline, 29392710). Increase oxcarbazepine-induced SJS/TEN (CPIC guideline, 29392710). Increased lamotrogine-induced SJS/TEN (meta-analysis, 25428396). Increased phenytoin-induced SJS/TEN (moderate association, 23692434). PMID 26094938 HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701 and Abacavir hypersensitivity. 25934581, 22378157 HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 PMID 32714190 (review article) HLA-B*57:01, carbamazepine and SJS/TEN. HLA-B*15:11, carbamazepine and SJS/TEN. HLA-B*13:01, dapsone and DRESS (29458119); to: HLA-B*15:02: Increased carbamazepine-induced SJS/TEN (CPIC guideline, 29392710). Increase oxcarbazepine-induced SJS/TEN (CPIC guideline, 29392710). Increased lamotrogine-induced SJS/TEN (meta-analysis, 25428396). Increased phenytoin-induced SJS/TEN (moderate association, 23692434). PMID 26094938 HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701 and Abacavir hypersensitivity. 25934581, 22378157 HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 PMID 32714190 (review article) HLA-B*57:01, carbamazepine and SJS/TEN. HLA-B*15:11, carbamazepine and SJS/TEN. HLA-B*13:01, dapsone and DRESS (29458119) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.50 | HLA-B |
David Metz changed review comment from: HLA-B*15:02: Increased carbamazepine-induced SJS/TEN (CPIC guideline, 29392710). Increase oxcarbazepine-induced SJS/TEN (CPIC guideline, 29392710). Increased lamotrogine-induced SJS/TEN (meta-analysis, 25428396). Increased phenytoin-induced SJS/TEN (moderate association, 23692434). PMID 26094938 HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701 and Abacavir hypersensitivity. 25934581, 22378157 HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 PMID 32714190 (review article) HLA-B*57:01, carbamazepine and SJS/TEN. HLA-B*15:11, carbamazepine and SJS/TEN. HLA-B*31:01, carbamazepine and DRESS. HLA-B*13:01, dapsone and DRESS (29458119) PMID 32714190 (review article) Phenytoin and B*15:02, B*13:01, B*51:01 (? strength) Others (beta-lactams, fluclox, augmentin, nevirapine).; to: HLA-B*15:02: Increased carbamazepine-induced SJS/TEN (CPIC guideline, 29392710). Increase oxcarbazepine-induced SJS/TEN (CPIC guideline, 29392710). Increased lamotrogine-induced SJS/TEN (meta-analysis, 25428396). Increased phenytoin-induced SJS/TEN (moderate association, 23692434). PMID 26094938 HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701 and Abacavir hypersensitivity. 25934581, 22378157 HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 PMID 32714190 (review article) HLA-B*57:01, carbamazepine and SJS/TEN. HLA-B*15:11, carbamazepine and SJS/TEN. HLA-B*13:01, dapsone and DRESS (29458119) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.50 | HLA-B |
David Metz changed review comment from: HLA-B*15:02: Increased carbamazepine-induced SJS/TEN (CPIC guideline, 29392710). Increase oxcarbazepine-induced SJS/TEN (CPIC guideline, 29392710). Increased lamotrogine-induced SJS/TEN (meta-analysis, 25428396). Increased phenytoin-induced SJS/TEN (moderate association, 23692434). PMID 26094938 HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701 and Abacavir hypersensitivity. 25934581, 22378157 HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 PMID 32714190 (review article) HLA-B*57:01, carbamazepine and SJS/TEN. HLA-B*15:11, carbamazepine and SJS/TEN. HLA-B*31:01, carbamazepine and DRESS. HLA-B*13:01, dapsone and DRESS (29458119) PMID 32714190 (review article) Phenytoin and B*15:02, B*13:01, B*51:01 (? strength) Others (beta-lactams, fluclox, augmentin, nevirapine).; to: HLA-B*15:02: Increased carbamazepine-induced SJS/TEN (CPIC guideline, 29392710). Increase oxcarbazepine-induced SJS/TEN (CPIC guideline, 29392710). Increased lamotrogine-induced SJS/TEN (meta-analysis, 25428396). Increased phenytoin-induced SJS/TEN (moderate association, 23692434). PMID 26094938 HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701 and Abacavir hypersensitivity. 25934581, 22378157 HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 PMID 32714190 (review article) HLA-B*57:01, carbamazepine and SJS/TEN. HLA-B*15:11, carbamazepine and SJS/TEN. HLA-B*31:01, carbamazepine and DRESS. HLA-B*13:01, dapsone and DRESS (29458119) PMID 32714190 (review article) Phenytoin and B*15:02, B*13:01, B*51:01 (? strength) Others (beta-lactams, fluclox, augmentin, nevirapine). |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.50 | HLA-B |
David Metz changed review comment from: HLA-B*15:02 positive: Increased carbamazepine-induced SJS/TEN (CPIC guideline, 29392710). Increase oxcarbazepine-induced SJS/TEN (CPIC guideline, 29392710). Increased lamotrogine-induced SJS/TEN (meta-analysis, 25428396). PMID 26094938 Strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701 and Abacavir hypersensitivity. PMID: 25934581 PMID: 22378157 HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810; to: HLA-B*15:02: Increased carbamazepine-induced SJS/TEN (CPIC guideline, 29392710). Increase oxcarbazepine-induced SJS/TEN (CPIC guideline, 29392710). Increased lamotrogine-induced SJS/TEN (meta-analysis, 25428396). Increased phenytoin-induced SJS/TEN (moderate association, 23692434). PMID 26094938 HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701 and Abacavir hypersensitivity. 25934581, 22378157 HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 PMID 32714190 (review article) HLA-B*57:01, carbamazepine and SJS/TEN. HLA-B*15:11, carbamazepine and SJS/TEN. HLA-B*31:01, carbamazepine and DRESS. HLA-B*13:01, dapsone and DRESS (29458119) PMID 32714190 (review article) Phenytoin and B*15:02, B*13:01, B*51:01 (? strength) Others (beta-lactams, fluclox, augmentin, nevirapine). |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.50 | HLA-B |
David Metz changed review comment from: PMID 29392710 HLA-B*15:02 positive: Greater risk of carbamazepine-induced SJS/TEN. Greater risk of oxcarbazepine induced SJS/TEN PMID 26094938 Strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701 and Abacavir hypersensitivity. HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810; to: HLA-B*15:02 positive: Increased carbamazepine-induced SJS/TEN (CPIC guideline, 29392710). Increase oxcarbazepine-induced SJS/TEN (CPIC guideline, 29392710). Increased lamotrogine-induced SJS/TEN (meta-analysis, 25428396). PMID 26094938 Strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701 and Abacavir hypersensitivity. PMID: 25934581 PMID: 22378157 HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.45 | HLA-B | Zornitza Stark Publications for gene: HLA-B were set to 25099164; 23695185; 29392710 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | HLA-B |
David Metz changed review comment from: PMID 29392710 HLA-B*15:02 positive: Greater risk of carbamazepine-induced SJS/TEN. Greater risk of oxcarbazepine induced SJS/TEN PMID 26094938 Strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810; to: PMID 29392710 HLA-B*15:02 positive: Greater risk of carbamazepine-induced SJS/TEN. Greater risk of oxcarbazepine induced SJS/TEN PMID 26094938 Strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701 and Abacavir hypersensitivity. HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | HLA-B |
David Metz changed review comment from: PMID 29392710 HLA-B*15:02 positive: Greater risk of carbamazepine-induced SJS/TEN. Greater risk of oxcarbazepine induced SJS/TEN PMID 26094938 Strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810; to: PMID 29392710 HLA-B*15:02 positive: Greater risk of carbamazepine-induced SJS/TEN. Greater risk of oxcarbazepine induced SJS/TEN PMID 26094938 Strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN PMID: 23232549 Carrier of HLA-B*5801 (HLA-B*5801/*X,b HLA-B*5801/HLA-B*5801), significant increase in risk of allopurinol induced SCAR (severe cutaneous adverse reaction). HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | HLA-B |
David Metz changed review comment from: PMID 29392710 HLA-B*15:02 positive: Greater risk of carbamazepine-induced SJS/TEN. Greater risk of oxcarbazepine induced SJS/TEN PMID 26094938 Strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810; to: PMID 29392710 HLA-B*15:02 positive: Greater risk of carbamazepine-induced SJS/TEN. Greater risk of oxcarbazepine induced SJS/TEN PMID 26094938 Strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | HLA-B | David Metz Deleted their comment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | HLA-B |
David Metz changed review comment from: Strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN (26094938) HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810; to: PMID 29392710 HLA-B*15:02 positive: Greater risk of carbamazepine-induced SJS/TEN. Greater risk of oxcarbazepine induced SJS/TEN PMID 26094938 Strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | HLA-A |
David Metz changed review comment from: Carbamazepine/Oxcarbazapine. HLA-B*15:02 or HLA-A*31:01 a/w increase risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). HLA-A*31:01 a/w with risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE).; to: PMID 29392710 HLA-A*31:01 positive: Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE (maculopapular exanthema) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | HLA-A |
David Metz changed review comment from: Carbamazepine/Oxcarbazapine. At least one copy of either HLA-B*15:02 or HLA-A*31:01 associated with increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). HLA-A*31:01 also associated with risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE).; to: Carbamazepine/Oxcarbazapine. HLA-B*15:02 or HLA-A*31:01 a/w increase risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). HLA-A*31:01 a/w with risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE). |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | HLA-B |
David Metz edited their review of gene: HLA-B: Added comment: Strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN (26094938) HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals). https://www.pharmgkb.org/chemical/PA164781042/guidelineAnnotation/PA166182810; Changed publications: 26094938 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | HLA-B | David Metz commented on gene: HLA-B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.28 | HLA-B | Zornitza Stark Publications for gene: HLA-B were set to 25099164; 23695185 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.27 | HLA-B | Zornitza Stark edited their review of gene: HLA-B: Changed publications: 25099164, 23695185, 29392710 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.25 | HLA-B | Zornitza Stark edited their review of gene: HLA-B: Changed publications: 25099164, 23695185 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.25 | HLA-B | Zornitza Stark Publications for gene: HLA-B were set to 25099164 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.24 | HLA-B | Zornitza Stark edited their review of gene: HLA-B: Changed publications: 23695185 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.24 | HLA-B | Zornitza Stark Publications for gene: HLA-B were set to | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.23 | HLA-B | Zornitza Stark edited their review of gene: HLA-B: Changed publications: 25099164 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.14 | HLA-B | Zornitza Stark Marked gene: HLA-B as ready | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.14 | HLA-B | Zornitza Stark Gene: hla-b has been classified as Green List (High Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.14 | HLA-B | Zornitza Stark Classified gene: HLA-B as Green List (high evidence) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.14 | HLA-B | Zornitza Stark Gene: hla-b has been classified as Green List (High Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.13 | HLA-B |
Zornitza Stark gene: HLA-B was added gene: HLA-B was added to Pharmacogenomics_Paediatric. Sources: Expert list Mode of inheritance for gene: HLA-B was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted Phenotypes for gene: HLA-B were set to Carbamazepine; Oxcarbamazepine; Phenytoin Review for gene: HLA-B was set to GREEN Added comment: HLA-B*1502 Sources: Expert list |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||